| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281393 | Clinical Gastroenterology and Hepatology | 2016 | 49 Pages |
Abstract
The use of NSBBs was not associated with a significant increase in all-cause mortality in patients with cirrhosis and ascites or refractory ascites. Certainty in the available estimates is low; a randomized trial of only patients with ascites is needed to answer this question. This meta-analysis does not support the position that NSBBs routinely be withheld from patients with ascites.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Sakkarin Chirapongsathorn, Nelson Valentin, Fares Alahdab, Chayakrit Krittanawong, Patricia J. Erwin, Mohammad H. Murad, Patrick S. Kamath,